OncoMir Library Cancer Type Target Gene

Similar documents
Table S1: Analysis of Notch gene rearrangements in triple negative breast cancer subtypes

EMT: Epithelial Mesenchimal Transition

Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making

10/31/2017. micrornas and cancer. From the one gene-one enzyme hypothesis to. microrna DNA RNA. Transcription factors.

Diagnostic test Suggested website label Description Hospitals available

Review Article MicroRNAs in cancer treatment and prognosis

Genetics and Cancer Ch 20

THE HALLMARKS OF CANCER

List of Available TMAs in the PRN

SUPPLEMENTARY INFORMATION

FACULTY MEMBERSHIP APPLICATION Tulane Cancer Center

Out-Patient Billing CPT Codes

Antitumor Activity of CUDC-305, a Novel Oral HSP90 Inhibitor, in Solid and Hematological Tumor Xenograft Models

Cancer in Huron County

Negative Regulation of c-myc Oncogenic Activity Through the Tumor Suppressor PP2A-B56α

Cell Cycle and Cancer

Harmesh Naik, MD. Hope Cancer Clinic PERSONALIZED CANCER TREATMENT USING LATEST IN MOLECULAR BIOLOGY

Targeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018

Epidemiology in Texas 2006 Annual Report. Cancer

Cancer Genetics. What is Cancer? Cancer Classification. Medical Genetics. Uncontrolled growth of cells. Not all tumors are cancerous

H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS

Your single-source laboratory solution. FISH Probe Library

Clinical Grade Genomic Profiling: The Time Has Come

TUMOR M ARKERS MARKERS

Phosphorylation Site Company Cat #

SALSA MLPA probemix P175-A3 Tumour Gain Lot A3-0714: As compared to the previous version A2 (lot A2-0411), nine probes have a small change in length.

MicroRNA e tumorigenesi: diagnosi, prognosi e terapia

Tumor responses (patients responding/ patients treated)

Tumor Markers & Cytopathology

A class of genes that normally suppress cell proliferation. p53 and Rb..ect. suppressor gene products can release cells. hyperproliferation.

Molecular Cell Biology. Prof. D. Karunagaran. Department of Biotechnology. Indian Institute of Technology Madras

Pancreatic Cancer Research and HMGB1 Signaling Pathway

The Cancer Genome Atlas Pan-cancer analysis Katherine A. Hoadley

Regarding techniques of proteomics, there is:

Biology of cancer development in the GI tract

Biochemistry of Carcinogenesis. Lecture # 35 Alexander N. Koval

Supplementary Appendix

Cancer genetics

The mutations that drive cancer. Paul Edwards. Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge

NFκB What is it and What s the deal with radicals?

Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar

Supplementary Figure 1: Func8onal Network Analysis of Kinases Significantly Modulated by MERS CoV Infec8on and Conserved Across All Time Points

Species Tumor Type Comment for in vivo work Lead Time for in vivo studies [weeks] MB-49-luc-2 Mouse urinary bladder carcinoma C57BL/6 2

Additional file 2 List of pathway from PID

Cell, Volume 141. Supplemental Information Cell Signaling by Receptor Tyrosine Kinases Mark A. Lemmon and Joseph Schlessinger

EGFR: fundamenteel en klinisch

Annual Flash Report (unaudited) Fiscal Year ended March 31, 2017

Fusion Analysis of Solid Tumors Reveals Novel Rearrangements in Breast Carcinomas

VIII Curso Internacional del PIRRECV. Some molecular mechanisms of cancer

Individualized Cancer Therapy: Drug Treatment Testing before Therapy

Response and resistance to BRAF inhibitors in melanoma

SUPPLEMENTARY INFORMATION

Deregulation of signal transduction and cell cycle in Cancer

Late regulation of immune genes and micrornas in circulating leukocytes in a pig model of

Cancer. The fundamental defect is. unregulated cell division. Properties of Cancerous Cells. Causes of Cancer. Altered growth and proliferation

Oncogenes and Tumor Suppressors MCB 5068 November 12, 2013 Jason Weber

Cancer. The fundamental defect is. unregulated cell division. Properties of Cancerous Cells. Causes of Cancer. Altered growth and proliferation

Lecture 8 Neoplasia II. Dr. Nabila Hamdi MD, PhD

Cancer prevalence. Chapter 7

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December

Case Study - Informatics

Outcomes Report: Accountability Measures and Quality Improvements

Cell Polarity and Cancer

mirna(microrna) Expression and Detection

Contents. Preface XV Acknowledgments XXI List of Abbreviations XXIII About the Companion Website XXIX

BRCAplus. genetic testing for hereditary breast cancer

CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION

Table S5. Literature of association between non-cancer genes or complexes in cancer-related marketing centrality motifs and cancers.

Macmillan Publications

Cutaneous metastases. Thaddeus Mully. University of California, San Francisco Professor, Departments of Pathology and Dermatology

Pathway Map Reference Guide

micrornas!as! Biomarkers! Landscape!

GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer

Karyotype analysis reveals transloction of chromosome 22 to 9 in CML chronic myelogenous leukemia has fusion protein Bcr-Abl

1. The metastatic cascade. 3. Pathologic features of metastasis. 4. Therapeutic ramifications. Which malignant cells will metastasize?

YB-1: oncoprotein, prognostic marker and therapeutic target?

Corporate Medical Policy

Cell cycle, signaling to cell cycle, and molecular basis of oncogenesis

If multiple KRAS mutation tests have been performed, refer to the most recent test results.

GYNplus. genetic testing for hereditary ovarian and/or uterine cancer

August 17, Dear Valued Client:

One-two Punch to Deadly Pancreatic Cancer: Targeted Therapy with Mab AR9.6 and Rapamycin Analogue ACP Jan 2016

mirna Dr. S Hosseini-Asl

oncogenes-and- tumour-suppressor-genes)

Development status of ONO-4538(nivolumab)1

Changes from Third Quarter Flash Report for the Fiscal Year ending March 2015 announced on February 3, 2015 *1: Marketing authorization of Onoact 150

Cell Reproduction Virtual Lab. Interphase Prophase Metaphase Anaphase Telophase. Name

Exploring TCGA Pan-Cancer Data at the UCSC Cancer Genomics Browser

DENOMINATOR: Adult patients with metastatic colorectal cancer who have a RAS (KRAS or NRAS) gene mutation

Seeds and soil theory by Stephen Paget at the end of the XIX century.

Follicular Lymphoma. ced3 APOPTOSIS. *In the nematode Caenorhabditis elegans 131 of the organism's 1031 cells die during development.

Tumor Markers Yesterday, Today & Tomorrow. Steven E. Zimmerman M.D. Vice President & Chief Medical Director

Review Article Regulation of Breast Cancer and Bone Metastasis by MicroRNAs

SUPPLEMENTARY INFORMATION

Phase-specific Costs of Cancer Care in Ontario

Development Pipeline Progress Status. February 1, 2019

The Panel Approach to Diagnostics. Lauren Hopson International Product Specialist Cell Marque Corporation

Oncology 101. Cancer Basics

Reduced expression of SOX7 in ovarian cancer: a novel tumor suppressor through the Wnt/β-catenin signaling pathway

Nature Medicine: doi: /nm.3559

Transcription:

OncoMir Library Cancer Type Target Gene hsa-let-7a-1 Breast Cancer, Lung Cancer H RAS, HMGA2, CDK6, NRAS hsa-let-7a-2 Breast Cancer, Lung Cancer H RAS, HMGA2, CDK6, NRAS hsa-let-7a-3 Breast Cancer, Lung Cancer IGF II, IGFBP 3 hsa-let-7b Breast Cancer, Lung Cancer TLX, CyclinD1 hsa-let-7c Breast Cancer, Lung Cancer, prostrate Cancer BCl XL hsa-let-7d Head and Neck Squamous Cell Carcinoma D3R hsa-let-7e Breast Cancer, Lung Cancer H RAS, HMGA2, CDK6, NRAS hsa-let-7f-1 Breast Cancer, Lung Cancer, renal cell carcinoma H RAS, HMGA2, CDK6, NRAS hsa-let-7f-2 Breast Cancer, Lung Cancer H RAS, HMGA2, CDK6, NRAS hsa-let-7g Breast Cancer, Lung Cancer BCl XL hsa-let-7i Breast Cancer, Lung Cancer TLRs hsa-mir-1-1 Liver Cancer HDAC4, FOXp1 hsa-mir-7-1 Lung, breast, and glioblastoma p21 activated kinase 1, EGFR hsa-mir-7-2 Lung, breast, and glioblastoma p21 activated kinase 1, EGFR hsa-mir-7-3 Lung, breast, and glioblastoma p21 activated kinase 1, EGFR hsa-mir-9-1 Breast Cancer, Lung Cancer E cadherin hsa-mir-10a Breast Cancer HOXD10 hsa-mir-10b Breast Cancer HOXD10 hsa-mir-15a Prostrate Cancer BCl2 hsa-mir-15b Prostrate Cancer BCl2 hsa-mir-16-1 Prostrate Cancer BCl2 hsa-mir-16-2 Prostrate Cancer BCl2 hsa-mir-17 Breast Cancer Pten, AlB1 hsa-mir-18a Breast Cancer Pten hsa-mir-18b Breast Cancer Pten hsa-mir-19a Breast Cancer Pten hsa-mir-19b-2 Breast Cancer Pten hsa-mir-20a Prostrate Cancer,Breast Cancer E2F1 3 hsa-mir-20b Breast Cancer VEGF B hsa-mir-21 Breast Cancer PTEN, TPM1, PDCD4, Maspin hsa-mir-22 Breast Cancer estrogen receptor α

hsa-mir-23a Prostrate Cancer and Lymphoma E3 ubiquitin ligase MAFbx/atrogin 1 hsa-mir-23b Prostrate Cancer LaminB1 hsa-mir-24-1 Prostrate Cancer FAF1 hsa-mir-24-2 Prostrate Cancer FAF2 hsa-mir-25 Gastric, Prostrate, Pancreatic, Multiple Myeloma Integrin αv hsa-mir-26a-1 Leukemia, Pancreatic Cancer CCL19 hsa-mir-26a-2 Leukemia, Pancreatic Cancer CCL19 hsa-mir-26b Bladder Cancer, Pancreatic Cancer IL 6 hsa-mir-27a Breast Cancer, Skin Cancer ZBTB10, Myt 1, TSP1 hsa-mir-27b Breast Cancer, Skin Cancer ZBTB10, Myt 1, TSP2 hsa-mir-29a Lung Cancer TPP hsa-mir-29b-1 B Cell melignancy MCL hsa-mir-29b-2 B Cell melignancy MCL hsa-mir-29c Nasopharyngeal Carcinoma Extracellular Matrix Proteins hsa-mir-30a Lung Cancer TIMP2 hsa-mir-30b Pancreatic Cancer Prostein hsa-mir-30c-1 Breast Cancer Pten hsa-mir-34a Liver Cancer c Met hsa-mir-92a-1 Breast Cancer Integrin αv hsa-mir-92a-2 Breast Cancer Integrin αv hsa-mir-95 Prostrate Cancer Toll receptor6 hsa-mir-101 Prostrate Cancer EZH2 hsa-mir-103-1 Bladder Cancer, Pancreatic Cancer ARNT hsa-mir-106a Gastric Carcinoma IL 10 hsa-mir-106b Prostrate E2F1 3 hsa-mir-107 Colon Cancer, Pancreatic Cancer HIF 1 hsa-mir-122 Liver Cancer BCl w, Cyclin G1 hsa-mir-124-1 Lung Cancer Integrin βv hsa-mir-124-2 Lung Cancer Integrin βv hsa-mir-124-3 Lung Cancer Integrin βv hsa-mir-125a Ovarian Cancer EFGR hsa-mir-125b-1 Prostrate, Leukemia Bak1 / VEGF A hsa-mir-125b-2 Prostrate, Leukemia Bak1 / VEGF A

hsa-mir-126 Prostrate prostein hsa-mir-127 Leukemia CXCR5 hsa-mir-128-1 Leukemia VEGF B hsa-mir-128-2 Leukemia VEGF B hsa-mir-133a-1 Prostrate Cancer Rho hsa-mir-133a-2 Prostrate Cancer Rho hsa-mir-133b esophageal squamous cell carcinoma FSCN1 hsa-mir-134 Lung Cancer LIMK1 hsa-mir-135b Co rectal Cancer HIF 1 hsa-mir-136 Lung Cancer thrombospin 2 hsa-mir-137 Liver Cancer MITF hsa-mir-138-1 anaplastic thyroid carcinoma htert hsa-mir-138-2 anaplastic thyroid carcinoma htert hsa-mir-139 Colorectal cancer β Catenin hsa-mir-140 Colon Cancer HDAC4 hsa-mir-141 Human Ovarian cancer, gastic cancer TGFβ2 hsa-mir-142 Lung Cancer adenylyl cyclase (AC) 9 hsa-mir-143 B Cell melignancy ERK 5 hsa-mir-144 Skin Cancer unknown hsa-mir-145 Breast Cancer C myc, hsa-mir-146a Prostrate Cancer ROCK1 hsa-mir-150 Gastric Cancer P2X 7 hsa-mir-151 Colon Cancer RhoGDIA, hsa-mir-153-1 Lung Cancer Bcl 2, Mcl 1 hsa-mir-153-2 Lung Cancer Bcl 2, Mcl 1 hsa-mir-154 Lung Cancer myc, sp1, sp3 hsa-mir-155 Breast Cancer TP53 INP1 hsa-mir-181a-1 Breast Cancer, Pancreatic Cancer, Leukemia Hox A11 hsa-mir-181a-2 Breast Cancer, Pancreatic Cancer, Leukemia unknown hsa-mir-181b-1 Acute Lymphoblastic Leukemia, Breast Cancer BCL2 hsa-mir-181b-2 Acute Lymphoblastic Leukemia, Breast Cancer BCL2 hsa-mir-181c Pancreatic Cancer Notch4, KRAS

hsa-mir-181d Leukemia unknown hsa-mir-183 Skin Cancer FOXO3 hsa-mir-185 Lung Cancer unknown hsa-mir-188 Ovarian Tumor unknown hsa-mir-190 Pancreatic Cancer myc hsa-mir-191 Prostrate Cancer unknown hsa-mir-192 Stomach Cancer, Pancreatic Cancer SIP1 hsa-mir-194-1 Liver Cancer unknown hsa-mir-194-2 Liver Cancer unknown hsa-mir-195 Lymphoma Rb E2F signaling Pathway hsa-mir-196a-1 B Cell melignancy AnnexinA 1 hsa-mir-196a-2 B Cell melignancy AnnexinA 1 hsa-mir-198 Lung Cancer Cyclin T1 hsa-mir-199a-2 Lung Cancer, Pancreatic Cancer TIMP3 hsa-mir-200a Colorectal cancer β Catenin hsa-mir-200b Liver Cancer ZFHX1B hsa-mir-200c Lung Cancer, Breast Cancer E cadherin hsa-mir-202 Gastric Carcinoma Unknown hsa-mir-203 Pancreatic Cancer, Gastric Carcinoma p63 family hsa-mir-204 Pancreatic Cancer PDEF hsa-mir-205 Breast Cancer MED1 hsa-mir-206 Breast Cancer ER α hsa-mir-210 Breast Cancer and Melanoma tumors MNT hsa-mir-214 Ovarian Cancer PTEN hsa-mir-215 Colon Cancer Thymidine synthase hsa-mir-218-1 Gastric Carcinoma Robo1 receptor hsa-mir-218-2 Gastric Carcinoma Robo1 receptor hsa-mir-219-1 Myeloma NMDA receptor hsa-mir-219-2 Myeloma NMDA receptor hsa-mir-221 Prostrate Cancer, Liver Cancer p27/kip1, P57 hsa-mir-222 Prostrate Cancer p27/kip1 hsa-mir-223 Liver Cancer stathmin hsa-mir-224 Pancreatic Cancer, Liver Cancer apoptosis inhibitor 5

hsa-mir-296 Lung Cancer Human Growth Factor hsa-mir-326 Breast Cancer MDR hsa-mir-331 Prostrate Cancer ERBB 2 hsa-mir-335 Breast Cancer SOX4, PTPRN2, MERTK, TNC, ER α hsa-mir-372 Gastric Carcinoma LATS2 hsa-mir-373 esophageal cancer LATS2 hsa-mir-375 Pancreatic Cancer PI 3 kinase hsa-mir-424 Leukemia transcription factor PU.1 hsa-mir-425 Ovarian unknown hsa-mir-486 Pancreatic Cancer MRTF A hsa-mir-488 Lung Cancer unknown